The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Metformin and the Risk of Cancer
Open accessAbstract
OBJECTIVE: Time-related biases in observational studies of drug effects have been described extensively in different therapeutic areas but less so in diabetes. Immortal time bias, time-window bias, and time-lag bias all tend to greatly exaggerate the benefits observed with a drug. RESEARCH DESIGN AND METHODS: These time-related biases are described and shown to be prominent in observational studies that have associated metformin with impressive reductions in the incidence of and mortality from cancer. As a consequence, metformin received much attention as a potential anticancer agent; these observational studies sparked the conduction of randomized, controlled trials of metformin as cancer treatment. However, the spectacular effects reported in these studies are compatible with time-related biases. RESULTS: We found that 13 observational studies suffered from immortal time bias; 9 studies had not considered time-window bias, whereas other studies did not consider inherent time-lagging issues when comparing the first-line treatment metformin with second- or third-line treatments. These studies, subject to time-related biases that are avoidable with proper study design and data analysis, led to illusory extraordinarily significant effects, with reductions in cancer risk with metformin ranging from 20 to 94%. Three studies that avoided these biases reported no effect of metformin use on cancer incidence. CONCLUSIONS: Although observational studies are important to better understand the effects of drugs, their proper design and analysis is essential to avoid major time-related biases. With respect to metformin, the scientific evidence of its potential beneficial effects on cancer would need to be reassessed critically before embarking on further long and expensive trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Self-citationThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Immortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 584
Self-citationCancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Mortality After Incident Cancer in People With and Without Type 2 Diabetes
Currie, C. J., Poole, C. D., Jenkins-Jones, S., Gale, E. A. M., Johnson, J. A., & Morgan, C. L. (2012) · Diabetes Care · doi:10.2337/dc11-1313 · Cited by 398
Lee, M.-S., Hsu, C.-C., Wahlqvist, M. L., Tsai, H.-N., Chang, Y.-H., & Huang, Y.-C. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-20 · Cited by 380
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Metformin: A review of its metabolic effects
Cusi, K. J., & DeFronzo, R. A. (1998) · Diabetes reviews · Cited by 310
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A., Davila, M., Abdalla, E. K., Javle, M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 309
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 292
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Suissa, S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1231oc · Cited by 272
Self-citationLower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives
Ruiter, R., Visser, L. E., van Herk-Sukel, M. P. P., Coebergh, J.-W. W., Haak, H. R., Geelhoed-Duijvestijn, P. H., Straus, S. M. J. M., Herings, R. M. C., & Stricker, B. H. C. (2012) · Diabetes Care · doi:10.2337/dc11-0857 · Cited by 232
He, X., Esteva, F. J., Ensor, J., Hortobagyi, G. N., Lee, M.-H., & Yeung, S.-C. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr534 · Cited by 207
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
Lee, J. H., Kim, T. I., Jeon, S. M., Hong, S. P., Cheon, J. H., & Kim, W. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26421 · Cited by 204
Metformin in Breast Cancer: Time for Action
Goodwin, P. J., Ligibel, J. A., & Stambolic, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1630 · Cited by 200
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Ferrara, A., Lewis, J. D., Quesenberry, C. P., Peng, T., Strom, B. L., Van Den Eeden, S. K., Ehrlich, S. F., & Habel, L. A. (2011) · Diabetes Care · doi:10.2337/dc10-1067 · Cited by 181
Romero, I. L., McCormick, A., McEwen, K. A., Park, S., Karrison, T., Yamada, S. D., Pannain, S., & Lengyel, E. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182393ab3 · Cited by 177
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 177
Lung Cancer Risk Reduction After Smoking Cessation: Observations From a Prospective Cohort of Women
Ebbert, J. O., Yang, P., Vachon, C. M., Vierkant, R. A., Cerhan, J. R., Folsom, A. R., & Sellers, T. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.085 · Cited by 177
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176
Bowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
Use of metformin and the risk of ovarian cancer: A case–control analysis
Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.038 · Cited by 159
Garrett, C. R., Hassabo, H. M., Bhadkamkar, N. A., Wen, S., Baladandayuthapani, V., Kee, B. K., Eng, C., & Hassan, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.71 · Cited by 154
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 154
Bosco, J. L. F., Antonsen, S., Sørensen, H. T., Pedersen, L. H., & Lash, T. L. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0817 · Cited by 151
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell’Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 145
Self-citationAntidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Valentina, G. D., Gardenal, R., Mas, M. D., Casarin, P., Zanette, G., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2506 · Cited by 144
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.483 · Cited by 143
Lai, S., Liao, K., Chen, P., Tsai, P., Hsieh, D. P. H., & Chen, C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.10.002 · Cited by 138
Is it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 134
Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Monami, M., Colombi, C., Balzi, D., Dicembrini, I., Giannini, S., Melani, C., Vitale, V., Romano, D., Barchielli, A., Marchionni, N., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1287 · Cited by 111
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study
Murtola, T. J., Tammela, T. L. J., Lahtela, J. T., & Auvinen, A. P. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn190 · Cited by 107
Time-window Bias in Case-control Studies
Suissa, S., Dell’Aniello, S., Vahey, S., & Renoux, C. (2011) · Epidemiology · doi:10.1097/ede.0b013e3182093a0f · Cited by 105
Self-citationBodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0992-t · Cited by 100
The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes
Smiechowski, B., Azoulay, L., Yin, H., Pollak, M., & Suissa, S. (2012) · Diabetes Care · doi:10.2337/dc12-0740 · Cited by 89
Self-citationClinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 85
Chung, Y. W., Han, D. S., Park, K. H., Eun, C. S., Yoo, K.-S., & Park, C. K. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9184-1 · Cited by 79
Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes
Yang, X., So, W. Y., Ronald, C. W., Kong, A. P. S., Lee, H. M., Yu, L. W. L., Chow, C., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2010) · Diabetes Care · doi:10.2337/dc10-1509 · Cited by 68
Lehman, D. M., Lorenzo, C., Hernández, J., & Wang, C.-P. (2012) · Diabetes Care · doi:10.2337/dc11-1829 · Cited by 59
Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial
Higurashi, T., Takahashi, H., Endo, H., Hosono, K., Yamada, E., Ohkubo, H., Sakai, E., Uchiyama, T., Hata, Y., Fujisawa, N., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-118 · Cited by 55
Diabetes therapy and cancer risk: causal effects and other plausible explanations
Hernández–Díaz, S., & Adami, H. (2010) · Diabetologia · doi:10.1007/s00125-010-1675-2 · Cited by 52
Bias in observational study of the effectiveness of nasal corticosteroids in asthma
Suissa, S., & Ernst, P. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.12.1118 · Cited by 39
Self-citationNiraula, S., Pond, G. R., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Joshua, A. M. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.267 · Cited by 38
Buchs, A. E., & SILVERMAN, B. G. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.002 · Cited by 36
Geraldine, N., Marc, A., Truyers, C., Mathieu, C., Stefaan, B., Wami, W. M., & Buntinx, F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.002 · Cited by 30
Korean Type 2 Diabetes Patients have Multiple Adenomatous Polyps Compared to Non-diabetic Controls
Suh, S., Kang, M., Kim, M. Y., Chung, H. S., Kim, S. K., Hur, K. Y., Kim, J. H., Lee, M., Lee, M. K., & Kim, K. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.9.1196 · Cited by 26
Cited by
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
The burden and risks of emerging complications of diabetes mellitus
Tomic, D., Shaw, J. E., & Magliano, D. J. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00690-7 · Cited by 1,163
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 484
Metadata
- Authors
- Suissa, S., & Azoulay, L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-11-14
- Volume
- 35
- Issue
- 12
- Pages
- 2665-2673
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2013047715
- Cited by
- 531
- References
- 61
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.